CSL Says Many Issues Raised in 2010, 2011 FDA Audits Addressed

CSL Ltd. (CSL), the world’s second- biggest maker of blood-derived therapies, says many of the concerns raised in audits conducted by the U.S. Food and Drug Administration in 2010 and 2011 have been addressed.

“These aren’t new issues,” spokeswoman Sharon McHale said today after the Australian newspaper published a story saying the FDA raised concerns about CSL’s manufacturing practices. “These are routine inspections the FDA does, and aren’t a final determination of compliance.”

To contact the reporter on this story: Nichola Saminather in Sydney at nsaminather1@bloomberg.net

To contact the editor responsible for this story: Iain Wilson at iwilson2@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.